Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
E For L Aim PCLBKK:EFORL +9.09%36 3-1 Month Momentum % is N/A% as of Aug. 18, 2026. GuruFocus rates BKK:EFORL with a GF Score™ of 36/100 and a GF Value™ of ฿0.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 123 Medical Distribution companies, E For L Aim PCL ranks worse than 813007.32% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-18), E For L Aim PCL's 3-1 Month Momentum % is N/A%.
The industry rank for E For L Aim PCL's 3-1 Month Momentum % or its related term are showing as below:
BKK:EFORL's 3-1 Month Momentum % is not ranked *
in the Medical Distribution industry.
Industry Median: -2.16 * Ranked among companies with meaningful 3-1 Month Momentum % only.
E For L Aim PCL (BKK:EFORL) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
E For L Aim PCL 3-1 Month Momentum % Related Terms
BKK:EFORL vs MCK, COR, CAH: 3-1 Month Momentum % Comparison
For the Medical Distribution subindustry, E For L Aim PCL's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
E For L Aim PCL 3-1 Month Momentum % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where E For L Aim PCL's 3-1 Month Momentum % falls into.
E For L Aim PCL (BKK:EFORL) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
E For L Aim PCL (BKK:EFORL) has a 3-1 Month Momentum % of N/A% as of Aug. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on E For L Aim PCL and its competitors. According to the industry distribution chart, E For L Aim PCL ranks #999999 out of 123 companies in the Medical Distribution industry.
Is E For L Aim PCL's 3-1 Month Momentum % too high?
E For L Aim PCL's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, E For L Aim PCL ranks #999999 out of 123 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, E For L Aim PCL has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's 3-1 Month Momentum % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, E For L Aim PCL ranks #999999 out of 123 companies for 3-1 Month Momentum %. This places E For L Aim PCL in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Distribution company?
A good 3-1 Month Momentum % depends on the Medical Distribution industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on E For L Aim PCL and its competitors. E For L Aim PCL's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.15, compared to a current price of ฿0.12 — trading 20% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. E For L Aim PCL's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL), the current 3-1 Month Momentum % is N/A% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is E For L Aim PCL (BKK:EFORL) Overvalued in 2026?
Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued.
The current stock price of ฿0.12 is trading 20% below its estimated GF Value™ of ฿0.15.
GuruFocus considers E For L Aim PCL to be Modestly Undervalued.
Key valuation signals for BKK:EFORL:
3-1 Month Momentum %: N/A%
GF Value™: ฿0.15 vs. price of ฿0.12 (20% below fair value)
No single metric tells the full story. See the BKK:EFORL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
36GF Score
Get the complete analysis for BKK:EFORL
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EFORL has been successfully added to your 
